BMS bites at GentiBio’s next-gen regulatory T cells, betting $1.9B on 3 programs Elevated liver enzymes force Centessa to drop a second asset in two months Zai Lab to shop around CD47 after deciding to ‘deprioritize’ internal development A complex fracturing at Bone brings together inflammatory, orthopedic biotechs in reverse merger-type deal Disc inks Gemini merger, secures cash from starry VC syndicate to advance ex-AbbVie, Roche drugs Pursuing AbbVie and J&J, Innovent hits primary endpoint in phase 2 psoriasis trial Vyne to reevaluate pipeline after eczema trial fail uproots plans Novartis’ new rare disease drug Vijoice named as an ‘empty vessel poised to be filled’ Walmart has a new policy denying some telehealth prescriptions for controlled drugs. It's implicating patients in recovery BD teams up with Labcorp to develop new companion diagnostic tests using flow cytometry Bristol Myers, in close CAR-T race with J&J and Legend, touts Abecma win in earlier myeloma Merck selects Saama to add machine learning tech to drug development process Medical supplies company CCS moves into home-based diabetes care management Featured Story | By Max Bayer Bristol Myers Squibb is sold on GentiBio's engineered T-cell therapy, betting $1.9 billion on up to three programs. The deal comes a year after GentiBio hauled in more than $150 million in series A funds. read more |
| |
|---|
|
Top Stories By James Waldron Only two months after Centessa dropped its lead asset after one patient experienced elevated liver enzymes, the biotech has now culled an early-stage candidate over a similar adverse event. read more By Max Bayer Zai Lab has determined “due to the competitive landscape,” that internal development of monoclonal antibody ZL-1201 will be deprioritized. read more By Annalee Armstrong The orthopedics-focused biotech was out looking for, well, a bone. And it found one in Medsenic, which will combine with Bone Therapeutics in an all-stock, reverse merger-type deal that will create a newly named company: BioSenic. read more By Nick Paul Taylor Disc Medicine has secured cash to advance hematology assets picked up from AbbVie and Roche, inking a merger with the floundering Gemini Therapeutics and tapping a starry syndicate of VCs to extend its runway into 2025. read more By Nick Paul Taylor Innovent Biologics’ challenger to drugs including Johnson & Johnson’s Tremfya and AbbVie’s Skyrizi has cleared phase 2. The study found the anti-IL-23 monoclonal antibody, which is designed to be given less frequently than some rivals, outperformed placebo in terms of reducing psoriasis area and severity. read more By Gabrielle Masson Vyne Therapeutics’ lead asset has failed to improve the severity of mild-to-moderate atopic dermatitis, uprooting the biotech’s plans and sending the stock plummeting. read more By Ben Adams Gravity Branding chose a positive outlook when it named Novartis’ latest FDA-approved drug Vijoice but also set a deeper meaning. Vijoice “can be regarded as optimistic and life-affirming, but essentially, represents an empty vessel poised to be filled with relevant brand qualities,” the drug naming firm said. read more By Anastassia Gliadkovskaya Walmart is not accepting prescriptions for controlled substances written via telehealth without an in-person visit in the preceding 24 months, implicating virtual addiction treatment. Corporate policies that limit telehealth prescriptions “are a threat to patient safety and recovery,” said Anna Legreid Dopp with the American Society of Health-System Pharmacists. read more By Conor Hale The collaboration will see the medtech giant and Labcorp’s drug development division partner up with Big Pharma companies, with the goal of offering an end-to-end solution that spans the development, approval and distribution of diagnostic tests. read more By Angus Liu Bristol Myers Squibb is trumpeting a first-in-class win as it tries to move Abecma up in the line of multiple myeloma treatment. But it may wind up one step behind Johnson & Johnson and Legend Biotech in terms of treatment order. read more By Andrea Park Saama's Life Science Analytics Cloud is powered by cloud computing and machine learning artificial intelligence technologies, the latter of which was trained using more than 100 million clinical data points. read more By Heather Landi CCS, a company that provides medical supplies for individuals living with chronic conditions, is moving into home-based diabetes care management with coaching and monitoring services. Here's why the company's CEO believes CCS is well positioned to crack open the diabetes care market. read more Resources Sponsored by: Speid & Associates, Inc. The total immersion, transformative training will take place at the Harvard Club in Boston. VIRTUAL in real time is also available. Contingencies for COVID19 will apply. Register NOW for a large early bird discount www.drugstomarket.com/drugbootcamp. Sponsored by: Triangle Insights Group, LLC The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services. Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Free Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ | 